Company news

Beyond Air, Inc. (NASDAQ:XAIR) news

Every Beyond Air, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Beyond Air, Inc. stock analysis →

Press releases & updates

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone...

August 25, 2026

Beyond Air® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update

August 13, 2026

Beyond Air Schedules Conference Call to Discuss Financial Results for the Quarter Ended June 30, 2026

August 4, 2026

Beyond Air® Announces Up to $30.1 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules

July 30, 2026

Beyond Air® Reports Fourth Quarter and Full Year 2026 Financial Results and Provides Corporate Update

June 26, 2026

Beyond Air Schedules Fiscal Year End 2026 Financial Results Conference Call and Webcast

June 22, 2026

Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special Meeting

June 10, 2026

Beyond Air Receives Nasdaq Hearing Panel Decision Granting Continued Listing

June 1, 2026

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026

April 20, 2026

Beyond Air Expands Commercial Access for LungFit PH through a Purchasing Agreement with a Top 3 National Group Purchasing Organization

April 2, 2026

Beyond Air Expands Commercial Access for LungFit® PH Through a Purchasing Agreement with a Top 3 National Group Purchasing Organization (...

April 1, 2026

Beyond Air, Inc. Announces Resignation of Steve Lisi, CEO, and Appointment of Robert Goodman, Chief Commercial Officer, as CEO

March 26, 2026

Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial

March 17, 2026

Beyond Air to Participate in the 38th Annual Roth Conference in March

March 11, 2026

Beyond Air® Announces Termination of Agreement to Sell Its NeuroNOS Subsidiary to XTL Biopharmaceuticals Ltd.

March 10, 2026

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and ...

February 20, 2026

Beyond Air® Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update

February 13, 2026

Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be...

February 4, 2026

Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences

January 27, 2026

Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast

January 26, 2026

Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

January 14, 2026

Beyond Air® Appoints Dan Moorhead as Chief Financial Officer

December 30, 2025

Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil

December 17, 2025

Beyond Air® Announces Transition of Chief Financial Officer

November 26, 2025

Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update

November 10, 2025

Beyond Air® Secures Up to $32 Million to Accelerate Growth

November 5, 2025

Beyond Air Schedules Second Fiscal Quarter 2026 Financial Results Conference Call and Webcast

October 23, 2025

Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

September 22, 2025

Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds

September 8, 2025

Beyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

September 3, 2025

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in Japan

August 20, 2025

Beyond Air® Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2025

Beyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and Webcast

July 25, 2025

Beyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.

July 22, 2025

Beyond Air® Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

June 17, 2025

Beyond Air Submits FDA PMA Supplement for Next Generation LungFit® PH

June 16, 2025

Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast

May 20, 2025

Beyond Air Granted U.S. Patent Covering Treatment of NTM Infections Using gaseous Nitric Oxide (gNO)

April 24, 2025

Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients’ Ability to Safely Self-Admi...

April 9, 2025

Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site

March 31, 2025

Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH

March 11, 2025

Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

February 10, 2025

Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

February 5, 2025

Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast

January 27, 2025

Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia

January 24, 2025

Beyond Cancer Announces Approval by the Israeli Ministry of Health to Conduct a Phase 1b Clinical Trial Utilizing Low Volume Ultra-High C...

December 3, 2024

Beyond Air Receives CE Mark in Europe for the LungFit® PH System

December 2, 2024

Beyond Air® Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

November 11, 2024

Beyond Air® Schedules Second Fiscal Quarter 2025 Financial Results Conference Call and Webcast

October 29, 2024

Beyond Air Partners with Healthcare Links to Expand Access to LungFit® PH System Through Group Purchasing Organizations and Integrated De...

October 2, 2024

Older →